The development of molecular targeted drugs with radiation and chemotherapy is critically
important for improving the outcomes of patients with hard-to-treat, potentially curable …

The practice of radiation oncology is currently primarily based on precise technical delivery
of highly conformal, image-guided radiation treatments. The precision medicine revolution …

Molecular Targeted Radiosensitizers: Opportunities and Challenges provides the reader
with a comprehensive review of key pre-clinical research components required to identify …

The first annual workshop for preclinical and clinical development of radiosensitizers took
place at the National Cancer Institute on August 8–9, 2012. Radiotherapy is one of the most …

Use of radiation for cancer therapy began shortly after the discovery of X-rays in 1895.
Technological advances over the ensuing 120 years have enabled the development of …

There is a growing appreciation of the potential value of combining novel molecularly-
targeted drugs with radiotherapy or chemoradiotherapy. Such approaches have the …

It is estimated that in 2008 1.4 million patients in North America will be diagnosed with a
nonskin form of cancer (www. cancer. org), of which seventy-five percent will receive …

Over the past several years, significant technological and biological progress has been
made in radiation oncology with focus on the development of new treatment schemes to …

Large collections of annotated cancer cell lines are powerful tools for precisely matching
targeted drugs with genomic alterations that can be tested as biomarkers in the clinic …

Clonogenic assays evaluate the ability of single cells to proliferate and form colonies. This
process approximates the regrowth and recurrence of tumors after treatment with radiation …